News
GT Biopharma, Inc. (the "Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative ...
The PGIM Short-Term Corporate Bond Fund outperformed its benchmark Index, gross of fees, for Q1 2025. Click here to read the full commentary.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback